Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-11331340-B2
Application number	US-202016806936-A
Country	US
Kind code	B2
Filing date	Mar 2, 2020
Priority date	Jun 14, 2012
Publication date	May 17, 2022
Grant date	May 17, 2022

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A method of delivering a composition comprising:
injecting through a delivery device into a location with physiological pH environment a liquid embolic composition comprising a biocompatible polymer including a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, aminoethyl methacylate, aminopropyl methacylate, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof, a second monomer including an acrylate, acrylamide, a derivative thereof, or a combination thereof, a non-physiological pH solution and a visualization agent, and
wherein the biocompatible polymer is soluble in the non-physiological pH and precipitates when it reaches the physiological pH, wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules, or a combination thereof.

2. The method of claim 1 , wherein the visualization agent is a particulate.

3. The method of claim 1 , wherein the visualization agent has a concentration of about 5% to about 65%.

4. The method of claim 1 , wherein the biocompatible polymer includes a third monomer.

5. The method of claim 1 , wherein the biocompatible polymer is a reaction product of three different monomers.

6. The method of claim 1 , wherein the non-physiological pH solution is aqueous.

7. The method of claim 1 , wherein the non-physiological pH solution has a pH of less than about 5.

8. The method of claim 1 , wherein the biocompatible polymer has a concentration of about 1% w/w to about 35% w/w.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61K47/30

  Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61L24/046

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence) · CPC title

• A61K9/00 Primary

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• A61L2430/36

  for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title